Sunday, June 24, 2018

Living Beyond PKD, Need Kidney Donors, Medicaid Expansion Increased Kidney Transpalnts

Living Beyond PKD

From Newcastle Herald, Australia, by Helen Gregory

Hunter athlete fighting polycystic kidney disease tackles 24 hour obstacle course

Eyes on prize: Jillian Bellamy, pictured training at Merewether, enjoys the social aspect of endurance races. “It’s a safe zone, everyone wants to help each other and supports each other to get through it". Picture: Jonathan Carroll


JILLIAN Bellamy had just completed her second obstacle course when she realised some other competitors were pushing beyond her one lap.

“I thought ‘I want to do that!’,” she said. “I want to still be on an obstacle course at midnight wearing nothing but a headlamp!”

Ms Bellamy, 28, got her wish and competed in her first 24 hour endurance event in 2016.

The Rutherford primary school teacher will compete against 400 participants on Saturday – when showers are forecast – in the globe’s first 24 Hour Enduro OCR World Championships, to be held at Dargle Farm outside of Sydney.

The event includes completing as many laps of an 11 kilometre course as possible in 24 hours.

The course has 30 obstacles, ranging from crawling, to climbing ropes and carrying weights.

“I really like all the rope climbing – I have a lot of lower body strength rather than upper body strength,” she said.

“But I also like all the full body work - running, jumping and pushing myself over the top of a wall or getting down and crawling between tyres and barbed wire.”

Ms Bellamy said her determination to push her body to its limits came from her desire to focus on what it is capable of, instead of her polycystic kidney disease.

She was 15 when she received a “bombshell” diagnosis of the inherited disorder, where clusters of cysts develop within the kidneys, causing them to enlarge and lose function over time.

She was told she would need blood pressure medication, regular blood tests, to see a specialist and consult a nutritionist to cut almost all processed food from her diet.

For now, she said, the only symptom she has is pain when one of the cysts bursts.

“Health and fitness is a big distraction from the disease,” she said.

“It keeps me in control of what my body can do. I love these challenges so much because one day I won’t be able to do them. I want to do them now – and I will do them now.”

Ms Bellamy is aiming to complete seven or eight laps in the event.

She’s been training at least two hours a day every day since January, when she received medical clearance for a hip injury.

“You don’t know what to prepare for until you’re out there,” she said.

“You can do as much training as you like but you don’t know what’s going to hit until you’re on the course.

“The first year it was minus five degrees.

“I only had one outfit and I thought my fingers were going to fall off.

The second year it was raining and I thought ‘Why am I doing this?’

“You start counting down the minutes till the sun comes up and thinking about when you can have a hot shower and food.

“But when you finish it’s the best feeling.

“You’re walking like a penguin and all you can do is laugh.

“You think ‘I love this pain – I’m coming back again’.”




Kidney Donors & Transplants

From The Boston Herald, by Sean Philip Cotter

John Nucci's kidney transplant shines light on need for donors

GIFT OF LIFE: Kerri Abrams will donate a kidney to John Nucci today at Massachusetts General Hospital. Staff photo by Nicolaus Czarnecki



As John Nucci undergoes kidney transplant surgery today, advocates and doctors say there is a vital need for more donors — a cause the former city councilor says he will champion when he recovers.

Nucci, 66, of East Boston, was due to go under the knife early this morning at Massachusetts General Hospital alongside family friend Kerri Abrams, 37, of Arlington, who is donating one of her kidneys to him.

Nucci’s own kidneys are operating at just 2 percent due to his genetic polycystic kidney disease. He said yesterday he was confident as he prepared to go into surgery at Massachusetts General.

“They know what they’re doing,” Nucci said.

Dr. Elliot Heher, the medical director of MGH’s kidney donor team, said the number of people waiting for a kidney skyrocketed between 1998 and 2015 as advances in transplant medicine made getting a new kidney the ideal option rather than one of last resort.

“Now there’s absolutely no doubt that transplantation is preferred” to alternatives such as dialysis, Heher said. “It’s what we all would want for ourselves.”

The supply of kidneys, though, has not followed, Heher said. He said it’s remained relatively level for a couple of decades, so a gap has yawned between the supply and need for kidneys even though the spike in people looking for kidneys has plateaued since 2015. Some of the 83,978 on the list nationally may have to wait a decade for the organ.

Today’s surgery — removing a kidney from Abrams and transplanting it into Nucci, is expected to take three to four hours.

Typically, the operation involves doctors making a long incision on the side of each patient, according to the Johns Hopkins University.

The doctors usually have the kidney switch sides; if it comes from her right side, it will end up in his left, and vice versa. They do that because a flipped kidney allows the doctors better access to connecting all the internal tubes, according to Johns Hopkins.

Nucci said he’s hoping to be discharged as early as Friday.

Nucci said he plans on advocating for a law revision to change how people register as organ donors. He wants to make it so you have to opt out of being an organ donor rather than choosing to be one.

Nucci said he believes many people who aren’t registered as being possible organ donors in the event of their deaths would be just fine with someone making good use of their body parts after they’re gone.

“I was one of them,” Nucci said. He just recently had the Registry of Motor Vehicles put the little red heart on his driver’s license.

Paul Dooley, the head of a Canton-based organization called MatchingDonors.com that pairs up living donors and recipients, said as many as two dozen a day contact the nonprofit looking to donate a kidney out of the kindness of their hearts.

“It’s amazing — good people come forward,” Dooley said, adding that their motivations are often personal. “Someone lost a grandparent, they want to save a grandparent. Someone lost a nephew, they want to save a kid.”


Post Operation UPDATE

John Nucci says he already can feel his new kidney working.

“This great feeling just came over me after the surgery,” the former Boston city councilor said when reached by phone yesterday evening, as he recovered from Tuesday’s transplant surgery at Massachusetts General Hospital.

Nucci, 66, of East Boston, received a kidney from family friend Kerri Abrams, who volunteered to donate one of hers when she learned from a Herald article that Nucci was suffering from a rare genetic disorder and in dire need of one.

Surgeons at Massachusetts General Hospital carried out the procedure Tuesday over the course of a few hours, removing one of her kidneys and implanting it into Nucci.

Kidneys filter toxins out of the blood and produce urine. Nucci said the slow decline caused by his genetic polycystic kidney disease had left him chronically exhausted. Though he’s in some pain after the major surgery, Nucci said the strong new organ has swept all that away.

“It was like a fog had lifted,” Nucci said. “I forgot what it was like.”

Nucci said he’s hoping to be discharged sometime around this weekend.

Doctors 30 years ago diagnosed Nucci with the disease, which causes non-cancerous cysts to grow on a person’s kidneys until the organs ultimately fail. Nucci’s kidneys before the surgery were operating at 2 percent. Nucci inherited the condition from his father, who died from the illness at 64, and his three sons have all tested positive for the disease.




From Drexel University - Now, by By: Lauren Ingeno

Medicaid Expansion Under the ACA Increased Low-Income Patient Access to Kidney Transplants


After states expanded Medicaid to cover more low-income individuals under the Affordable Care Act (ACA), there was a significant boost in the number of chronic kidney disease patients with Medicaid coverage who were placed on the kidney transplant waiting list, according to a new study led by Drexel University researchers.

Medicaid expansion was associated with larger increases in Medicaid coverage among new listings of racial and ethnic minority patients compared to listings of white patients. This suggests that Medicaid expansion may have helped to curb racial and socioeconomic disparities in pre-dialysis chronic kidney disease care in the United States. The findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

More than 93,000 people are currently listed for a new kidney, according to the U.S. Department of Health and Human Services. While black and Hispanic Americans have higher rates of diabetes and high blood pressure than white Americans, putting them at risk for organ failure, historically patients who were white or had private health insurance were more likely to receive an organ transplant.

Kidney transplantation is more cost-effective and associated with better health outcomes than dialysis. Getting on the waiting list early can shorten the amount of time that kidney transplant candidates need to endure dialysis before getting a transplant, with average waiting times of five to seven years. However, access to the list is largely dependent on having health insurance coverage, and Medicare only provides a health insurance “safety net” for individuals without other insurance coverage after they start dialysis.

“The sooner you can get on the list, the sooner you may receive a transplant. However, before the ACA, the majority of patients who got on the waiting list before starting dialysis had private health insurance and were white, even though minorities are substantially more likely than white individuals to end up with late-stage kidney disease,” said the study’s lead author Meera Nair Harhay, MD, an assistant professor of medicine at Drexel University College of Medicine. “Given evidence that millions of low income and minority individuals gained insurance coverage by Medicaid expansion, I wondered whether Medicaid expansion was also changing the socioeconomic and racial makeup of the kidney transplant waitlist.”

January 1, 2014 marked the beginning of the full implementation of Medicaid expansion in the United States, when the federal government enhanced funding to states that elected to expand Medicaid to cover low-income adults at or below 138 percent of the federal poverty level. Using national data from the United Network of Organ Sharing database over a six-year period, Harhay and her colleagues compared trends in insurance types used for preemptive listings among U.S. states that did and did not expand Medicaid under the ACA. They also examined whether there was evidence of differences in insurance types used for preemptive listings of minorities compared to listings of white transplant candidates after Medicaid expansion

The researchers found that states that expanded their Medicaid programs experienced an increase in preemptive listings of Medicaid beneficiaries. States that fully implemented Medicaid expansion on January 1, 2014 had a 59 percent relative increase in Medicaid-covered preemptive listings (1,094 to 1,737 patients) from the pre-expansion (years 2011-2013) to post-expansion period (years 2014-2016), compared with an 8.8 percent relative increase among Medicaid non-expansion states. From the pre- to post-expansion period, the adjusted proportion of listings with Medicaid coverage increased by 3 percentage-points among expansion states and decreased by 0.3 percentage-points among non-expansion states.

“In states that did not expand Medicaid, millions of individuals with incomes too high to qualify for Medicaid and too low to receive subsidized private insurance remain uninsured,” the study authors write in their conclusion. “Given this coverage gap, it is uncertain if low-income individuals with chronic kidney disease in non-expansion states have had equivalent opportunities to accrue preemptive waiting time for kidney transplantation.”

The authors also found that in expansion states, the proportion of new black listings with Medicaid coverage increased by 4 percentage points, and the proportion of new Hispanic listings with Medicaid coverage increased by 5.9 percentage points, whereas the proportion of new white listings with Medicaid coverage increased by only 1.4 percentage points.

With respect to cost, the study authors note that U.S. spending for chronic dialysis currently exceeds 30 billion dollars per year.

“Policies, such as insurance expansion, that expand access to health care and kidney transplantation services for low-income patients could lessen the number of patients on dialysis and significantly reduce these costs,” said study co-author Ryan McKenna, PhD,an assistant professor at Drexel’s Dornsife School of Public Health. “Our study has shown that expanding Medicaid may provide a pathway to kidney transplantation for low income individuals with kidney disease,” Harhay said.

The study authors concluded that more research is needed to find out whether long-term transplant outcomes differ among candidates who were listed with expanded Medicaid coverage compared with those with other coverage options.

Sunday, June 3, 2018

Tolvaptan is Helping, PKD Research: Bardoxolone Methyl Clinical Study, Organs on Chips, ADPKD RouteMap for Patients

PKD Treatment

From WCVB, ABC Affiliate, Boston

'Revolutionary' drug offers first treatment for devastating kidney disease

Clinical trials in Boston show tolvaptan slows progression of hereditary PKD

For Claudia Iliescu, the trunk of her family tree might as well have the letters PKD carved into the base.

The acronym is shorthand for polycystic kidney disease.


"My grandmother had it," Iliescu said. "And many uncles and aunts and cousins of my mom had it."

She said about half of the relatives on her maternal side have been diagnosed.

"They had persistent, consistent pain," Iliescu said. "And complications."

Iliescu's family has an hereditary form of the disease called autosomal dominant PKD. It's progressive, causing fluid-filled cysts to develop and multiply in both kidneys.

"And as the cysts grow, you feel fullness in your abdomen," she said. "You cannot eat anymore very well because everything's compressed."

The disease has no cure. Instead, as the kidneys fail, patients undergo dialysis or a kidney transplant.

This poor prognosis has devastated Iliescu's family for generations. She remembers thinking that it's her turn now.

"It's always in the back of your head," she said. "You always think, 'OK, so this is what's coming and there's nothing I can do about it.'"

That changed when Dr. Ronald Perrone at Tufts Medical Center suggested she participate in clinical trials for the drug tolvaptan.

The treatment helped Iliescu. Now, the Food and Drug Administration agrees, it can help other patients, too.

"This is the first disease-modifying drug for polycystic kidney disease," Perrone said. "So it's really revolutionary."

Tolvaptan is now available under the brand name Jynarque.

The drug won't reverse the symptoms of PKD, but the trials showed it delays them. It also decreases the rate of kidney pain, stones and infections.

"For patients, it gives them some hope rather than the bleak future that many of them might have envisioned for themselves," Perrone said.

Even with the trial over, Iliescu continues to take tolvaptan. She still has cysts, but they don't appear to be growing.

"Even if I need a transplant or dialysis in my late 60s or 70s, that's a much better outcome than needing it earlier," Iliescu said. "Just slowing down the progression of the disease is fantastic."




PKD Research

From The Conversation



It doesn’t look like a kidney, but this ‘kidney-on-a-chip’ is a breakthrough for new drug testing. Alex Levine, CC BY-ND

Getting a new pharmaceutical from an idea in the chemistry lab to market takes many years and billions of dollars. Each year just several dozen new drugs are approved for use in the United States.

Human “organs-on-chips” are leading a revolution in drug safety testing. These devices use human cells to model the structure and function of human organs and tissues. By testing the potential effects of drugs on different organs faster than traditional methods, organs-on-chips can reduce the need for animal studies and better predict which new drugs will effectively treat human disease.

As part of an interdisciplinary research team, we’re working on a kidney-on-a-chip to improve our understanding of how kidney diseases begin and which drugs can safely treat them.

Quicker and better testing

Historically, laboratory testing for new drugs is performed in cells grown in dishes or flasks. If a drug passes initial screening tests in vitro, researchers next test it in vivo in live animals to determine the effects of a new drug on a whole system instead of just one cell type at a time. Finally, after many years of laboratory investigation, researchers will test a promising new drug in people to see if it is safe and effective.

The problem is 9 out of 10 of these drugs never make it from small-scale human tests to the patient because they turn out to be ineffective or toxic, even if they showed promising results in early testing.

Organs-on-chips have the potential to completely transform that system. Ranging from the size of a fingernail to that of a credit card, they’re composed of fluid channels and tiny chambers that contain human cell samples. Organs-on-chips in development in labs around the country include kidney, lung, liver, intestine, skin, brain, heart, bone and reproductive systems.

In an organ-on-a-chip, flowing liquid supplies the cells with oxygen and nutrients, similar to the way blood sustains cells in the human body. It’s this constant flow that makes these devices special. Cells grown in organs-on-chips devices act more like cells in a human organ than do cells grown in flat dishes without flow.
Fluid circulates through a kidney-on-a-chip. Alex Levine, CC BY-ND


Case of the kidney-on-a-chip

Kidneys are incredibly important to overall human health. The two fist-sized kidneys remove drugs and unwanted compounds from the body and play a critical role in maintaining proper salt and water balance, blood pressure and vitamin D and bone health. Genetic conditions and even commonly administered medications can, in some circumstances, damage the kidneys.

In the U.S., 15 percent of adults have kidney diseases. But most don’t even know it, because kidney diseases often display no symptoms until the condition is very advanced. There’s a pressing need to understand how kidney disease begins, and to develop new safe and effective treatments.

Here at the University of Washington, our kidney-on-a-chip research team is composed of scientists from many different disciplines, including pharmacy, pharmaceutical sciences, nephrology (kidney medicine), toxicology, biochemistry and bioengineering.

In partnership with Nortis, Inc., a local biotechnology company, our team has created a small device — the size of a business card — with up to three tiny tubes, each one-thousandth the size of a drop of water, containing 5,000 human kidney cells. When tiny amounts of fluid are pumped through the tubes, the kidney cells are exposed to important signals that help the cells in the chip behave as if they were in a live kidney.

We’ve found that the kidney cells release signals – called biomarkers – of injury when exposed to known kidney toxins. Our research showed that cells on the chip released markers of injury commonly seen in the urine of people with kidney damage. Testing with the older method, using cells on plates, did not show any damage with the same treatment. This suggests that the kidney-on-a-chip may be better than existing methods at predicting if a new drug will cause kidney damage in humans.

Connecting organs-on-chips to mimic systems

Now that we’ve had these promising results, scientific teams across the country are starting to connect different organs together to replicate a more complex, multi-organ system, to give greater insights into how drugs affect people. For example, we were able to connect a liver-on-a-chip to a kidney-on-a-chip to learn how a plant extract used in some herbal medicines, called aristolochic acid, damages kidney cells. This chip-to-chip investigation reinforces the need for interconnected organs-on-a-chip to replicate the complex mechanics in the human body.

In the coming year, our kidney-on-a-chip project will be one of several sent to the International Space Station where low gravity speeds up changes in cells, sometimes causing health problems for astronauts. The Space Station could be the perfect place to find out more about kidney diseases in weeks, rather than years or decades.

Organs-on-chips can also be used to discover new drug targets. Our team is evaluating the kidney-on-a-chip as a tool to personalize drug selection and dosing in people with kidney cancer, polycystic kidney disease and chronic kidney disease. Other organs-on-chips labs around the country are studying diseases of the immune system, brain, lungs, heart and blood vessels. By working together, dozens of research teams are developing this new technology to revolutionize drug discovery, leading to the development of better and safer medications for all.



From Nasdaq.com, Press release

Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study


Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a clinical-stage biopharmaceutical company, today announced that positive interim data from the autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy cohorts of the ongoing, open-label, Phase 2 PHOENIX trial are being presented by Pablo E. Pergola, M.D., Ph.D., Research Director, Renal Associates, PA, San Antonio, at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) meeting in Copenhagen.

The ADPKD cohort of PHOENIX enrolled 31 patients, and available data demonstrate that bardoxolone methyl (bardoxolone) significantly improved kidney function in ADPKD patients as measured by their estimated glomerular filtration rate (eGFR). Bardoxolone-treated patients showed a mean improvement of 6.6 mL/min/1.73 m2 at Week 4 (n=31; p<0.0001), increasing to 12.0 mL/min/1.73 m2 at Week 12 (n=8; p<0.0001) from a mean baseline eGFR of 47.7 mL/min/1.73 m2. The IgA nephropathy cohort enrolled 26 patients, and data were reported through Week 8. Bardoxolone-treated patients showed a mean improvement of 8.4 mL/min/1.73 m2 at Week 8 (n=9; p<0.0001) from a mean baseline eGFR of 46.2 mL/min/1.73 m2. No drug-related serious adverse events have been reported, and reported adverse events have generally been mild to moderate in intensity. Full data for the primary endpoint of change in eGFR at Week 12 for the ADPKD, IgA nephropathy, and type 1 diabetic chronic kidney disease (CKD) cohorts of PHOENIX will be available in the third quarter of 2018.

"Bardoxolone has now produced large improvements in kidney function in a high percentage of patients spanning 11 trials and five different forms of chronic kidney disease," said Dr. Pergola. "These observations suggest that bardoxolone is addressing pathogenic pathways of inflammation and fibrosis that contribute to the loss of kidney function in patients with chronic kidney disease."

Additionally, Dr. Christoph Wanner, M.D., Chief of the Division of Nephrology and Hypertension at the University Hospital of Würzburg, Germany, gave an oral presentation at ERA-EDTA entitled "Bardoxolone Methyl Prevents eGFR Decline in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes ─ Post-hoc Analyses from BEACON." The analysis demonstrated that patients randomized to bardoxolone were more than 50 percent less likely than patients receiving placebo to experience events that predict kidney failure. The authors of the abstract concluded that bardoxolone preserves kidney function and may delay the onset of kidney failure in patients with type 2 diabetes and stage 4 CKD. The abstract was named a Ten Best Abstract by the Paper Selection Committee of ERA-EDTA.

"Bardoxolone's improvements in kidney function in patients with ADPKD and IgA nephropathy are consistent with improvements observed in other forms of CKD, which have been durable and predictive of retained eGFR benefit after withdrawal of drug in prior trials," said Colin Meyer, M.D., Reata's Chief Medical Officer. "Additionally, selection of the BEACON outcomes analysis for oral presentation at one the world's top nephrology meetings, six years after BEACON concluded, reinforces the importance of the study's results. The durable increases in eGFR associated with a 50 percent reduction in outcomes inspire optimism for bardoxolone's potential to delay or prevent dialysis in CKD."




Living with PKD

From Great Reporter

Launch of the ADPKD Patient Routemap: an interactive new resource to help empower patients and families


ERA-EDTA Congress 2018 sees the launch of the ADPKD Patient Route Map, an interactive resource designed to help educate and empower people affected by autosomal dominant polycystic kidney disease (ADPKD).

‘The ADPKD Patient Route Map is a great example of how patients and experts can work together’, says Tess Harris, PKD International President and an ADPKD patient. ‘Ultimately the idea is to help everyone affected by ADPKD cope better with the disease and get all the care, support and information they need, at the right time’.

The ADPKD Patient Route Map is freely available to download from the PKD International website (www.pkdinternational.org/adpkd-route-map).

The Route Map explains the types of care and support that patients and families should expect from their health service. The aim is to help patients and carers to manage their own health with their healthcare team, to talk about ADPKD with their nephrologist, to participate in making decisions about their own care, and to make the best use of available care and support services.

The Route Map was developed jointly by the European ADPKD Forum (EAF). EAF is an international group of experts from the fields of nephrology, genetics, hepatology and advocacy, and PKD International, the international ADPKD patient support group alliance.

The idea for the Route Map came from an EAF Round Table meeting involving patients and representatives from various European-level societies of medical specialists involved in ADPKD care and kidney patient organisations, in January 2016. The resulting ‘EAF Multidisciplinary Position Statement on ADPKD Care ’, recently published in the April edition of Nephrology Dialysis and Transplantation, explains the principles and evidence base for the Route Map.

The Route Map presents in lay terms what ADPKD is, how it is diagnosed, assessed and managed over the course of the disease – including self-care measures that patients can take to stay as healthy as possible. It also covers kidney complications (such as cyst infections and kidney stones), pain management and major non-kidney manifestations (such as liver cysts). It gives advice on issues such as genetics and genetic testing, family planning, and coping with the effects of ADPKD on wellbeing, work and finances. Finally, it outlines opportunities for patients to participate in research, registries and highlights the role of the European Rare Kidney Disease Network (ERKNet).

As Prof. Albert Ong (Sheffield, UK), a co-author of the Route Map put it: ‘We’ve tried to map out ADPKD along the course of a lifetime. What’s great about the Route Map is that it’s not just a book of facts – it’s attractive and interactive, allowing people to look at different topics according to the different stages of their own journey.’

The Route Map allows readers to reveal further information on key topics and messages of advice, experience and support provided by patients and their family members across Europe. Checklists are provided to help patients and families get the most out of consultations, and healthcare teams ensure that patients are always at the centre of their care pathway.

Co-author Dr Vicente Torres (Rochester, MN, USA) said: ‘The Route Map should be very useful to nephrologists – to help us to inform and empower our patients and to ensure that our services are truly patient-centred.’